149 related articles for article (PubMed ID: 26459532)
1. The pharmacokinetics of lopinavir/ritonavir when given with isoniazid in South African HIV-infected individuals.
Decloedt EH; van der Walt JS; McIlleron H; Wiesner L; Maartens G
Int J Tuberc Lung Dis; 2015 Oct; 19(10):1194-6. PubMed ID: 26459532
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis.
van der Laan LE; Garcia-Prats AJ; Schaaf HS; Tikiso T; Wiesner L; de Kock M; Winckler J; Norman J; McIlleron H; Denti P; Hesseling AC
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133558
[TBL] [Abstract][Full Text] [Related]
3. The pharmacokinetics of nevirapine when given with isoniazid in South African HIV-infected individuals.
Decloedt EH; Mwansa-Kambafwile J; van der Walt JS; McIlleron H; Denti P; Smith P; Wiesner L; Rangaka M; Wilkinson RJ; Maartens G
Int J Tuberc Lung Dis; 2013 Mar; 17(3):333-5. PubMed ID: 23407222
[TBL] [Abstract][Full Text] [Related]
4. Co-administration of a commonly used Zimbabwean herbal treatment (African potato) does not alter the pharmacokinetics of lopinavir/ritonavir.
Gwaza L; Aweeka F; Greenblatt R; Lizak P; Huang L; Guglielmo BJ
Int J Infect Dis; 2013 Oct; 17(10):e857-61. PubMed ID: 23587599
[TBL] [Abstract][Full Text] [Related]
5. Coadministration of lopinavir/ritonavir and rifampicin in HIV and tuberculosis co-infected adults in South Africa.
Murphy RA; Marconi VC; Gandhi RT; Kuritzkes DR; Sunpath H
PLoS One; 2012; 7(9):e44793. PubMed ID: 23028623
[TBL] [Abstract][Full Text] [Related]
6. Steady-state pharmacokinetics of lopinavir plus ritonavir when administered under different meal conditions in HIV-infected Ugandan adults.
Lamorde M; Byakika-Kibwika P; Boffito M; Nabukeera L; Mayito J; Ogwal-Okeng J; Tjia J; Back D; Khoo S; Ryan M; Merry C
J Acquir Immune Defic Syndr; 2012 Jul; 60(3):295-8. PubMed ID: 22481601
[TBL] [Abstract][Full Text] [Related]
7. Abacavir Exposure in Children Cotreated for Tuberculosis with Rifampin and Superboosted Lopinavir-Ritonavir.
Rabie H; Tikiso T; Lee J; Fairlie L; Strehlau R; Bobat R; Liberty A; McIlleron H; Andrieux-Meyer I; Cotton M; Lallemant M; Denti P
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32071055
[TBL] [Abstract][Full Text] [Related]
8. Population Pharmacokinetics of Lopinavir/Ritonavir: Changes Across Formulations and Human Development From Infancy Through Adulthood.
Yang J; Nikanjam M; Best BM; Pinto J; Chadwick EG; Daar ES; Havens PL; Rakhmanina N; Capparelli EV
J Clin Pharmacol; 2018 Dec; 58(12):1604-1617. PubMed ID: 30252146
[TBL] [Abstract][Full Text] [Related]
9. Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.
Dahourou DL; Amorissani-Folquet M; Malateste K; Amani-Bosse C; Coulibaly M; Seguin-Devaux C; Toni T; Ouédraogo R; Blanche S; Yonaba C; Eboua F; Lepage P; Avit D; Ouédraogo S; Van de Perre P; N'Gbeche S; Kalmogho A; Salamon R; Meda N; Timité-Konan M; Leroy V;
BMC Med; 2017 Apr; 15(1):85. PubMed ID: 28434406
[TBL] [Abstract][Full Text] [Related]
10. The safety, effectiveness and concentrations of adjusted lopinavir/ritonavir in HIV-infected adults on rifampicin-based antitubercular therapy.
Decloedt EH; Maartens G; Smith P; Merry C; Bango F; McIlleron H
PLoS One; 2012; 7(3):e32173. PubMed ID: 22412856
[TBL] [Abstract][Full Text] [Related]
11. Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug-resistant tuberculosis.
Brill MJ; Svensson EM; Pandie M; Maartens G; Karlsson MO
Int J Antimicrob Agents; 2017 Feb; 49(2):212-217. PubMed ID: 28038962
[TBL] [Abstract][Full Text] [Related]
12. Absence of circadian variation in the pharmacokinetics of lopinavir/ritonavir given as a once daily dosing regimen in HIV-1-infected patients.
van Heeswijk RP; Bourbeau M; Seguin I; Giguere P; Garber GE; Cameron DW
Br J Clin Pharmacol; 2005 Apr; 59(4):398-404. PubMed ID: 15801934
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of plasma lopinavir and ritonavir in tuberculosis-HIV co-infected African adult patients also receiving rifabutin 150 or 300 mg three times per week.
Ouedraogo HG; Matteelli A; Sulis G; Compaore TR; Diagbouga S; Tiendrebeogo S; Roggi A; Cisse K; Giorgetti PF; Villani P; Sangare L; Simpore J; Regazzi M; Kouanda S
Ann Clin Microbiol Antimicrob; 2020 Jan; 19(1):3. PubMed ID: 31969147
[TBL] [Abstract][Full Text] [Related]
14. The pharmacokinetics and acceptability of lopinavir/ritonavir minitab sprinkles, tablets, and syrups in african HIV-infected children.
Musiime V; Fillekes Q; Kekitiinwa A; Kendall L; Keishanyu R; Namuddu R; Young N; Opilo W; Lallemant M; Walker AS; Burger D; Gibb DM
J Acquir Immune Defic Syndr; 2014 Jun; 66(2):148-54. PubMed ID: 24828266
[TBL] [Abstract][Full Text] [Related]
15. Concentration-response model of lopinavir/ritonavir in HIV-1-infected pediatric patients.
Bouazza N; Urien S; Blanche S; Hirt D; Foissac F; Benaboud S; Tréluyer JM; Frange P
Pediatr Infect Dis J; 2014 Aug; 33(8):e213-8. PubMed ID: 24509655
[TBL] [Abstract][Full Text] [Related]
16. Low dose lopinavir/ritonavir tablet achieves adequate pharmacokinetic parameters in HIV-infected Thai adolescents.
Klinklom A; Puthanakit T; Gorowara M; Phasomsap C; Kerr S; Sriheara C; Ananworanich J; Burger D; Ruxrungtham K; Pancharoen C
Antivir Ther; 2012; 17(2):283-9. PubMed ID: 22293065
[TBL] [Abstract][Full Text] [Related]
17. Lopinavir/ritonavir plus lamivudine and abacavir or zidovudine dose ratios for paediatric fixed-dose combinations.
Bouazza N; Foissac F; Fauchet F; Burger D; Kiechel JR; Treluyer JM; Capparelli EV; Lallemant M; Urien S
Antivir Ther; 2015; 20(2):225-33. PubMed ID: 25279808
[TBL] [Abstract][Full Text] [Related]
18. Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV- infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapy.
Naiker S; Connolly C; Wiesner L; Kellerman T; Reddy T; Harries A; McIlleron H; Lienhardt C; Pym A
BMC Pharmacol Toxicol; 2014 Nov; 15():61. PubMed ID: 25406657
[TBL] [Abstract][Full Text] [Related]
19. ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir.
Lubomirov R; di Iulio J; Fayet A; Colombo S; Martinez R; Marzolini C; Furrer H; Vernazza P; Calmy A; Cavassini M; Ledergerber B; Rentsch K; Descombes P; Buclin T; Decosterd LA; Csajka C; Telenti A;
Pharmacogenet Genomics; 2010 Apr; 20(4):217-30. PubMed ID: 20139798
[TBL] [Abstract][Full Text] [Related]
20. [Positioning of lopinavir/ritonavir in antiretroviral treatment schemes].
Camacho Á; Rivero A
Enferm Infecc Microbiol Clin; 2014 Nov; 32 Suppl 3():31-4. PubMed ID: 25542874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
